Caption Management, LLC Arrowhead Pharmaceuticals, Inc. Put Options Transaction History

Caption Management, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$19.36 - $29.54 $2.25 Million - $3.44 Million	-116,400 Reduced 82.32%	25,000 $484,000
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $3.09 Million - $3.99 Million	141,400 New	141,400 $3.67 Million
Q4 2023 Feb 14, 2024	SELL	$21.2 - $31.03 $159,000 - $232,725	-7,500 Reduced 25.0%	22,500 $688,000
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $710,400 - $1.16 Million	30,000 New	30,000 $762,000
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $1.67 Million - $3.04 Million	-60,000 Reduced 57.14%	45,000 $1.58 Million
Q1 2022 May 13, 2022	BUY	$39.62 - $69.97 $1.93 Million - $3.41 Million	48,800 Added 86.83%	105,000 $4.83 Million
Q4 2021 Feb 11, 2022	BUY	$58.09 - $82.51 $1.81 Million - $2.57 Million	31,200 Added 124.8%	56,200 $3.73 Million
Q3 2021 Nov 12, 2021	SELL	$58.38 - $84.96 $2.74 Million - $3.98 Million	-46,900 Reduced 65.23%	25,000 $1.56 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $4.47 Million - $6.49 Million	71,900 New	71,900 $5.95 Million
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $1.84 Million - $2.71 Million	-30,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $787,800 - $1.05 Million	30,000 New	30,000 $845,000

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.